<DOC>
	<DOCNO>NCT00176631</DOCNO>
	<brief_summary>RATIONALE : Licorice root extract contain ingredient may slow growth tumor cell . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving licorice root extract together docetaxel may effective treatment prostate cancer . PURPOSE : This phase II trial study side effect well give licorice root extract together docetaxel work treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Licorice Root Extract Docetaxel Treating Patients With Metastatic Prostate Cancer That Did Not Respond Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy toxicity licorice root extract combination docetaxel patient hormone-refractory metastatic prostate cancer . Secondary - Determine ability licorice root extract alter surrogate marker estrogen activity cytotoxicity patient . OUTLINE : Patients receive docetaxel IV 1 hour day 1 oral licorice root extract 3 time day day 1-21 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis prostate adenocarcinoma Metastatic disease Must fail initial hormonal therapy disease progression least one chemotherapy regimen* , meet follow criterion : Progressive PSA ≥ 5 ng/mL , evidence 2 separate measurement take ≥ 2 week apart second PSA measurement great first one PSA measurement screen great first one Progressive measurable disease ( e.g. , change size lymph node parenchymal mass appearance new lesion physical examination xray/CT scan ) PSA level screen ≥ 5 ng/mL Progressive bone metastasis ( e.g. , presence new lesion bone scan ) PSA level screen ≥ 5 ng/mL NOTE : *Prior chemotherapy must include taxane therapy , disease progression follow taxane therapy Patients must maintain primary androgen ablation ( hormonal ) therapy AND experience disease progression receive antiandrogen therapy PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 6 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,500/mm^3 Bilirubin ≤ 1.2 mg/dL Creatinine ≤ 1.5 mg/dL SGOT SGPT ≤ 1.5 time upper limit normal No prior malignancy unless treat curative intent free disease time period consider appropriate specific cancer No uncontrolled hypertension No active infection No know HIV positivity No uncontrolled medical condition would preclude study therapy No diagnosis major depression suicidal ideation No problem oral absorption PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior surgery radiotherapy recover At least 4 week since prior flutamide At least 6 week since prior bicalutamide No prior concurrent herbal supplement thiazide diuretic No concurrent investigational commercial agent therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>